OBJECTIVE: The aim of the Prevention of Cervical Cancer in Tanzania (PROTECT) study is to assess the prevalence of oncogenic human papillomavirus (HPV) and to determine the type distribution among women in the general population according to human immunodeficiency virus (HIV) status, in preparation for a potential HPV immunization program. METHODS: We included 3603 women from the general population in urban and rural areas of Tanzania. All women underwent a gynecological examination where a Pap smear was obtained and cervical cells were collected to assess the presence of high-risk (HR) HPV DNA by hybrid capture 2 test. Genotyping was performed by the LiPaExtra method. These women were also tested for HIV. RESULTS: The prevalence of HR HPV types was 20.1%, ranging from 14.8% in women with normal cytology to 94.2% in women with high grade squamous intraepithelial lesion (HSIL) or worse (100% in 5 cancers). In women with normal cytology or low-grade lesions, the most common type was HPV52 (3.2%), followed by HPV16 (2.1%). In contrast, HPV16 was the dominating type in HSIL or worse (32.8%). No cancers contained HPV52. The HR HPV prevalence was higher in HIV-positive women (46.7%) than in HIV-negative women (17.2%). No specific HR HPV types were significantly more common in HIV-positive women. CONCLUSION: The HPV type distribution is similar in HIV-positive and HIV-negative women. These results suggest that the HPV vaccines that are currently available could protect women from HPV infection independently of their HIV status.
OBJECTIVE: The aim of the Prevention of Cervical Cancer in Tanzania (PROTECT) study is to assess the prevalence of oncogenic human papillomavirus (HPV) and to determine the type distribution among women in the general population according to human immunodeficiency virus (HIV) status, in preparation for a potential HPV immunization program. METHODS: We included 3603 women from the general population in urban and rural areas of Tanzania. All women underwent a gynecological examination where a Pap smear was obtained and cervical cells were collected to assess the presence of high-risk (HR) HPV DNA by hybrid capture 2 test. Genotyping was performed by the LiPaExtra method. These women were also tested for HIV. RESULTS: The prevalence of HR HPV types was 20.1%, ranging from 14.8% in women with normal cytology to 94.2% in women with high grade squamous intraepithelial lesion (HSIL) or worse (100% in 5 cancers). In women with normal cytology or low-grade lesions, the most common type was HPV52 (3.2%), followed by HPV16 (2.1%). In contrast, HPV16 was the dominating type in HSIL or worse (32.8%). No cancers contained HPV52. The HR HPV prevalence was higher in HIV-positive women (46.7%) than in HIV-negative women (17.2%). No specific HR HPV types were significantly more common in HIV-positive women. CONCLUSION: The HPV type distribution is similar in HIV-positive and HIV-negative women. These results suggest that the HPV vaccines that are currently available could protect women from HPV infection independently of their HIV status.
Authors: Pragna Patel; Charles E Rose; Pamela Y Collins; Bernardo Nuche-Berenguer; Vikrant V Sahasrabuddhe; Emmanuel Peprah; Susan Vorkoper; Sonak D Pastakia; Dianne Rausch; Naomi S Levitt Journal: AIDS Date: 2018-07-01 Impact factor: 4.177
Authors: R A Hanisch; P S Sow; M Toure; A Dem; B Dembele; P Toure; R L Winer; J P Hughes; G S Gottlieb; Q Feng; N B Kiviat; S E Hawes Journal: J Clin Virol Date: 2013-10-18 Impact factor: 3.168
Authors: Eun Kyoung Park; Heerim Cho; Sun Hee Lee; Seung Geun Lee; Sang Yeup Lee; Ki Hyung Kim; Chang Hun Lee; Joo Seop Chung; Ihm Soo Kwak Journal: J Korean Med Sci Date: 2013-12-26 Impact factor: 2.153
Authors: Santiago Neme; Elizabeth Wahome; Grace Mwashigadi; Alexander N Thiong'o; Joanne D Stekler; Anna Wald; Eduard J Sanders; Susan M Graham Journal: Open Forum Infect Dis Date: 2015-05-12 Impact factor: 3.835
Authors: Rebecca Kemunto Ogembo; Philimon Nyakauru Gona; Alaina J Seymour; Henry Soo-Min Park; Paul A Bain; Louise Maranda; Javier Gordon Ogembo Journal: PLoS One Date: 2015-04-14 Impact factor: 3.240
Authors: Aaron Ermel; Yan Tong; Phillip Tonui; Omenge Orang'o; Kapten Muthoka; Nelson Wong; Titus Manai; Stephen Kiptoo; Patrick J Loehrer; Darron R Brown Journal: Int J STD AIDS Date: 2021-07-07 Impact factor: 1.359
Authors: Catherine F Houlihan; Silvia de Sanjosé; Kathy Baisley; John Changalucha; David A Ross; Saidi Kapiga; Jose M Godinez; Ivana Bozicevic; Richard J Hayes; Deborah Watson-Jones Journal: J Infect Dis Date: 2014-04-16 Impact factor: 5.226